RxDoctor Payments Data

Shayla Sharmin

Family · Sugar Land, TXNPI 1104460070

Payments from drug & device makers

$2,491in general payments, 2019–2025

Across 125 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477
  • Lilly USA, LLC$468
  • Novo Nordisk$350
  • Merck$165
  • Amgen$165
  • Bayer$121
  • plus $745 from 16 others

What the payments were for

  • Food & beverage$2,47499%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,491 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$86,159
OzempicSemaglutide70$83,622
JanuviaSitagliptin Phosphate43$51,964
JardianceEmpagliflozin47$46,994
EliquisApixaban15$22,634
RybelsusSemaglutide12$11,465
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,574
Tresiba Flextouch U-100Insulin Degludec14$6,185
VascepaIcosapent Ethyl16$3,915
Rosuvastatin Calcium126$2,762
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,272
Fluocinonide12$2,049
Potassium Chloride54$1,803
Silver Sulfadiazine20$1,579
Celecoxib13$1,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$350$95,08782 claims
Lilly USA, LLCMounjaro$468$86,15972 claims
MerckJanuvia$165$51,96443 claims
Boehringer IngelheimJardiance$95$46,99447 claims
PfizerEliquis$82$22,63415 claims
GSKTrelegy Ellipta$16$10,57415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →